Combination of MiR-378 and MiR-210 serum levels enables sensitive detection of renal cell carcinoma

International Journal of Molecular Sciences

Volumn 16, Issue 10, 2015, Pages 23382-23389

  Fedorko, Michal ^a   Stanik, Michal ^b   Iliev, Robert ^b,c   Redova Lojova, Martina ^c   Machackova, Tana ^c   Svoboda, Marek ^b   Pacik, Dalibor ^a   Dolezel, Jan ^b   Slaby, Ondrej ^b,c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Biomarker; Blood serum; MicroRNA; Renal cell carcinoma

Indexed keywords

MICRORNA 210; MICRORNA 378; UNCLASSIFIED DRUG; MICRORNA; MIRN210 MICRORNA, HUMAN; MIRN378 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; MIDDLE AGED;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED;

EID: 84942916942     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161023382     Document Type: Article

References (17)

1. Yi, Z.; Fu, Y.; Zhao, S.; Zhang, X.; Ma, C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J. Cancer Res. Clin. Oncol. 2010, 136, 855–862.
2. Eble, J.N.; Sauter, G.; Epstein, J.I.; Sesterhenn, I.A. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. In World Health Organization Classification of Tumours; IARC Press: Lyon, France, 2004; p. 7.
3. Pichler, M.; Hutterer, G.C.; Chromecki, T.F.; Jesche, J.; Kampel-Kettner, K.; Eberhard, K.; Hoefler, G.; Pummer, K.; Zigeuner, R. Trends of stage, grade, histology and tumour necrosis in renal cell carcinoma in a European centre surgical series from 1984 to 2010. J. Clin. Pathol. 2012, 65, 721–724.
4. Pichler, M.; Hutterer, G.C.; Chromecki, T.F.; Jesche, J.; Kampel-Kettner, K.; Pummer, K.; Zigeuner, R. Renal cell carcinoma stage migration in a single European centre over 25 years: Effects on 5- and 10-year metastasis-free survival. Int. Urol. Nephrol. 2012, 44, 997–1004.
5. Esquela-Kerscher, A.; Slack, F.J. Oncomirs—MicroRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269.
6. Taylor, D.D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110, 13–21.
7. Redova, M.; Poprach, A.; Nekvindova, J.; Iliev, R.; Radova, L.; Lakomy, R.; Svoboda, M.; Vyzula, R.; Slaby, O. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 2012, 10, 55.
8. Redova, M.; Poprach, A.; Besse, A.; Iliev, R.; Nekvindova, J.; Lakomy, R.; Radova L.; Svoboda, M.; Dolezel, J.; Vyzula, R.; et al. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 2013, 34, 481–491.
9. Iwamoto, H.; Kanda, Y.; Sejima, T.; Osaki, M.; Okada, F.; Takenaka, A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int. J. Oncol. 2014, 44, 53–58.
10. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518.
11. Mahn, R.; Heukamp, L.C.; Rogenhofer, S.; von Ruecker, A.; Müller, S.C.; Ellinger, J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011, 77, e9–e16.
12. Huang, Z.; Huang, D.; Ni, S.; Peng, Z.; Sheng, W.; Du, X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127, 118–126.
13. Heneghan, H.M.; Miller, N.; Lowery, A.J.; Sweeney, K.J.; Newell, J.; Kerin, M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2011, 251, 499–505.
14. Hauser, S.; Wulfken, L.M.; Holdenrieder, S.; Moritz, R.; Ohlmann, C.H.; Jung, V.; Becker, F.; Herrmann, E.; Walgenbach-Brünagel, G.; von Ruecker, A.; et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 2012, 36, 391–394.
15. Zhao, A.; Li, G.; Péoc’h, M.; Genin, C.; Gigante, M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp. Mol. Pathol. 2013, 294, 115–120.
16. Zanutto, S.; Pizzamiglio, S.; Ghilotti, M.; Bertan, C.; Ravagnani, F.; Perrone, F.; Leo, E.; Pilotti, S.; Verderio, P.; Gariboldi, M, et al. Circulating miR-378 in plasma: A reliable, haemolysis independent biomarker for colorectal cancer. Br. J. Cancer 2014, 110, 1001–1007.
17. Wang, K.; Yuan, Y.; Cho, J.H.; McClarty, S.; Baxter, D.; Galas, D.J. Comparing the microRNA spectrum between serum and plasma. PLoS ONE 2012, 7, e41561.